Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Lung Cancer · Extensive-stage Small-cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Principal Investigator (You Lu, MD)Min Yu, MD (Sub-investigator)
Study leads
You Lu, MD
Principal Investigator
West China Hospital